Jennifer Ruddock | Senior Vice President of Investor Relations |
Howard Robin | President and Chief Executive Officer |
Gil Labrucherie | Senior Vice President and Chief Financial Officer |
Steven Doberstein | Head of R&D |
Jonathan Zalevsky | Chief Scientific Officer |
Mary Tagliaferri | Chief Medical Officer |
Chris Shibutani | Cowen |
Jessica Fye | JP Morgan |
George Farmer | BMO Capital Markets |
Difei Yang | Mizuho Securities |
Tyler Van Buren | Piper Jaffray |
Andy Hsieh | William Blair |
Paul Choi | Goldman Sachs |
David Steinberg | Jefferies |
Arlinda Lee | Canaccord |
Asthika Goonewardene | Asthika Goonewardene. |
Daina Graybosch | SVB Leerink |
Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference call may be recorded. I would now like to introduce your host for today's conference, Ms.